by azur2019wp | Sep 25, 2019 | News
Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, is Now Commercially Available for Pediatric Patients 6 Years of Age and Older WOBURN, Mass. (September 25, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe,...
by azur2019wp | Sep 11, 2019 | News
Azurity All-Hands Company Meeting WOBURN, Mass. (September 11, 2019) – This September two companies met and became one, Azurity Pharmaceuticals is the beginning of that new family. This was a time to meet and get to know each other and build as an organization....
by azur2019wp | Jul 10, 2019 | News
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for...
by azur2019wp | Jun 12, 2019 | News
CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals WOBURN, Mass. (June 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand...
Recent Comments